PLCG1 and prostate neoplasm: Inhibition of PLC-γ1 activity due to the expression of a dominant-negative PLCz molecule or the pharmacological PLC-γ1 inhibitor U73122 resulted in a reduction of the in vitro invasiveness of breast and prostate tumour cells (Kassis et al, 1999).